{"id":"W2518387705","doi":"10.1182/blood.v126.23.496.496","title":"Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Venetoclax; Obinutuzumab; Medicine; Open label; Off-label use; Internal medicine; Phases of clinical research; Phase (matter); Oncology; Randomized controlled trial; Clinical trial; Leukemia; Chronic lymphocytic leukemia; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002011272,0.0003009386,0.001470891,0.0001489277,0.0001053493,0.00003331398,0.0002445961,0.0001061389,0.000008081411],"category_scores_gemma":[0.002493168,0.0001619052,0.00003211481,0.0005518031,0.001367177,0.0001186192,0.000382299,0.0003460866,1.880633e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001850345,"about_ca_system_score_gemma":0.0056379,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003368119,"about_ca_topic_score_gemma":0.001436213,"domain_scores_codex":[0.9964902,0.0005523478,0.001180084,0.0005430653,0.0008573536,0.0003769237],"domain_scores_gemma":[0.996801,0.001457694,0.0004896139,0.0005146475,0.0003891237,0.0003479914],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9840549,0.003250127,0.005209533,0.0002788666,0.0004215574,0.00004780182,0.005919825,0.00003402807,0.00008419801,0.0000635293,0.00003894674,0.0005967111],"study_design_scores_gemma":[0.9788384,0.005103282,0.006658165,0.002330116,0.0005473045,0.00006877567,0.0005343199,0.005187578,0.000518022,0.00001237461,0.00003102521,0.000170632],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879343,0.0003757555,0.000009079761,0.0001430203,0.00002487892,0.01100163,0.000253402,0.00001098173,0.0002469746],"genre_scores_gemma":[0.9992912,0.00008464949,0.0002378548,0.0000394998,0.00002641244,0.0001712135,0.00008873046,0.00002902686,0.00003142726],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01135691,"threshold_uncertainty_score":0.9999992,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03257745358785442,"score_gpt":0.34248132132296,"score_spread":0.3099038677351056,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}